DeepMed Research

BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)

Phase 3

Completed

Conditions: Vasomotor Symptoms Associated With Menopause
Hot Flashes

Interventions: Drug: Elinzanetant (BAY3427080)
Drug: Placebo

First Posted Date: 2021-10-29

Last Posted Date: 2024-05-29

Lead Sponsor: Bayer

Target Recruit Count: 400

Registration Number: NCT05099159

Locations: 🇺🇸
Unified Women's Clinical Research - Raleigh, Raleigh, North Carolina, United States
🇺🇸
Clinical Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸
Metro Jackson OB-GYN, Jackson, Mississippi, United States

and more 92 locations

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Phase 1

Active, not recruiting

Conditions: EGFR Mutation
HER2 Mutation
Advanced Non-small Cell Lung Cancer

Interventions: Drug: BAY2927088_formulation A
Drug: BAY2927088_formulation B_1
Drug: BAY2927088_formulation B_2

First Posted Date: 2021-10-29

Last Posted Date: 2025-05-13

Lead Sponsor: Bayer

Target Recruit Count: 370

Registration Number: NCT05099172

Locations: 🇪🇸
Centro Integral Oncológico Clara Campal, Madrid, Spain
🇪🇸
Hospital Universitari i Politecnic La Fe | Oncologia, Valencia, Spain
🇨🇳
Chi-Mei Medical Center, Liouyine, Tainan, Taiwan

and more 79 locations

A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally

Phase 3

Completed

Conditions: Recurrent Herpes Labialis

Interventions: Drug: Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773
Drug: Placebo

First Posted Date: 2021-10-28

Last Posted Date: 2024-07-24

Lead Sponsor: Bayer

Target Recruit Count: 2019

Registration Number: NCT05098938

Locations: 🇺🇸
Science 37, Culver City, California, United States

A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately

Phase 1

Completed

Conditions: Children
Heart Failure

Interventions: Drug: Vericiguat (BAY1021189) - Intervention A
Drug: Vericiguat (BAY1021189) - Intervention B
Drug: Vericiguat (BAY1021189) - Intervention C
Drug: Vericiguat (Verquvo, BAY1021189) - Intervention D

First Posted Date: 2021-10-21

Last Posted Date: 2023-02-02

Lead Sponsor: Bayer

Target Recruit Count: 36

Registration Number: NCT05086952

Locations: 🇩🇪
SocraTec R&D GmbH, Erfurt, Thüringen, Germany

A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally

Phase 1

Completed

Conditions: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Interventions: Drug: Elinzanetant (BAY3427080)

First Posted Date: 2021-10-08

Last Posted Date: 2022-10-27

Lead Sponsor: Bayer

Target Recruit Count: 31

Registration Number: NCT05071729

Locations: 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function

Phase 1

Completed

Conditions: Contrast Enhancement in Magnetic Resonance Imaging

Interventions: Drug: BAY1747846

First Posted Date: 2021-09-30

Last Posted Date: 2022-11-21

Lead Sponsor: Bayer

Target Recruit Count: 24

Registration Number: NCT05061979

Locations: 🇺🇸
Alliance for Multispecialty Research, LLC - Knoxville, Knoxville, Tennessee, United States
🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

A Study to Gather Information About the Progress and Outcomes of Pregnancy in Women Using Various Vitamin Support Plans Before and During Pregnancy

Active, not recruiting

Conditions: Prevention of Vitamin Deficiency During and/or Before Pregnancy

Interventions: Dietary Supplement: Multivitamins (Elevit, BAY987808)
Dietary Supplement: Folic acid
Dietary Supplement: Multivitamins (Elevit, BAY2906300)
Drug: Multivitamins (Elevit, BAY987386)

First Posted Date: 2021-09-30

Last Posted Date: 2025-05-23

Lead Sponsor: Bayer

Target Recruit Count: 1500

Registration Number: NCT05062044

Locations: 🇺🇿
Many Locations, Multiple Locations, Uzbekistan

A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults

Phase 1

Completed

Conditions: Hot Flashes
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Interventions: Drug: Elinzanetant (BAY3427080)
Drug: Esomeprazole

First Posted Date: 2021-09-29

Last Posted Date: 2022-03-17

Lead Sponsor: Bayer

Target Recruit Count: 14

Registration Number: NCT05061563

Locations: 🇳🇱
PRAHealthSciences, Groningen, Netherlands

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

Phase 2

Active, not recruiting

Conditions: Metastatic Hormone-sensitive Prostate Cancer

Interventions: Drug: Darolutamide (BAY1841788, Nubeqa)
Other: ADT

First Posted Date: 2021-09-28

Last Posted Date: 2025-05-04

Lead Sponsor: Bayer

Target Recruit Count: 223

Registration Number: NCT05059236

Locations: 🇺🇸
Northwestern Medicine - Urology, Chicago, Illinois, United States
🇺🇸
New Jersey Urology - Voorhees, Voorhees, New Jersey, United States
🇺🇸
New Mexico Cancer Center - Albuquerque, Albuquerque, New Mexico, United States

and more 28 locations

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

Phase 3

Active, not recruiting

Conditions: Non-diabetic Chronic Kidney Disease

Interventions: Drug: Finerenone (BAY94-8862)
Drug: Placebo

First Posted Date: 2021-09-17

Last Posted Date: 2025-05-20

Lead Sponsor: Bayer

Target Recruit Count: 1584

Registration Number: NCT05047263

Locations: 🇧🇬
Diagnostic-Consultative Center XX | Nephrology Department, Sofia, Bulgaria
🇺🇸
Nephrology Consultants, LLC, Huntsville, Alabama, United States
🇺🇸
United Clinical Research & Innovations, S. Gate, California, United States

and more 323 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy